Frazier Life Sciences closed Fund XII at over $1.3 billion on July 31, 2025 — an oversubscribed biotech venture vehicle and one of July’s largest fund closes globally.

Key facts

• Firm: Frazier Life Sciences
• Date announced: July 31, 2025
• Fund size: $1.3B+ (oversubscribed)
• Focus: Company creation + early-stage biopharmaceuticals
• HQ: Palo Alto, CA
• Managing Partner: Patrick Heron

Investment strategy

Primarily company creation and early-stage private biopharma — consistent with prior FLS venture funds since the dedicated program launched in 2016.

Why this matters for NYC life sciences

NYC’s growing biotech cluster (Dimension Capital, Star51, etc.) benefits from downstream capital availability — Frazier’s $1.3B Fund XII adds significant dry powder for life sciences graduates from NYC seed platforms.

Sources

1. BusinessWire (July 31, 2025): https://www.businesswire.com/news/home/20250731285238/en/Frazier-Life-Sciences-Closes-Oversubscribed-1.3-Billion-Venture-Fund